Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Immutep Limited Stock

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.42 AUD -6.67% Intraday chart for Immutep Limited +18.31% +21.74%
Apr. 24 Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck MT
Apr. 24 Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B CI

Financials

Sales 2024 * 3.19M 2.08M Sales 2025 * 19.78M 12.92M Capitalization 499M 326M
Net income 2024 * -45M -29.39M Net income 2025 * -40M -26.13M EV / Sales 2024 * 132 x
Net cash position 2024 * 78.66M 51.38M Net cash position 2025 * 50.71M 33.12M EV / Sales 2025 * 22.7 x
P/E ratio 2024 *
-10.8 x
P/E ratio 2025 *
-12.2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.19%
More Fundamentals * Assessed data

Chart Immutep Limited

Dynamic Chart

Latest news about Immutep Limited

Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial MT
Encouraging results for Immutep's cancer therapies FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer CI
Immutep Doses First Patient in Cancer Trial MT
Immutep Limited Announces Change of Registered Office Address CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer CI
More news

Analyst Recommendations on Immutep Limited

Baird Initiates Immutep With Outperform Rating, $7 Price Target MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
More recommendations

Press releases Immutep Limited

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76 PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer AQ
Immutep : Corporate Presentation PU
More press releases

News in other languages on Immutep Limited

Pfizer : une étude clinique de phase I conduite avec Immutep
More news

Quotes and Performance

1 day-6.67%
1 week+18.31%
Current month+10.53%
1 month+13.51%
3 months+25.37%
6 months+33.33%
Current year+21.74%
More quotes

Highs and lows

1 week
0.34
Extreme 0.34
0.46
1 month
0.34
Extreme 0.34
0.46
Current year
0.33
Extreme 0.325
0.46
1 year
0.23
Extreme 0.225
0.46
3 years
0.23
Extreme 0.225
0.73
5 years
0.10
Extreme 0.1
0.73
10 years
0.10
Extreme 0.1
1.90
More quotes

Managers and Directors - Immutep Limited

Managers TitleAgeSince
Marc Voigt CEO
 Chief Executive Officer 51 10-12-31
David Fang DFI
 Director of Finance/CFO - 18-02-28
Florian Vogl CTO
 Chief Tech/Sci/R&D Officer - 23-04-30
Members of the board TitleAgeSince
Russell Howard CHM
 Chairman 74 13-05-07
Marc Voigt CEO
 Chief Executive Officer 51 10-12-31
Anne Anderson BRD
 Director/Board Member - Feb. 13
More insiders

Quotes

Date Price Change Volume
24-04-26 0.42 -6.67% 4,968,700
24-04-24 0.45 +16.88% 13,371,270
24-04-23 0.385 +8.45% 1,433,061
24-04-22 0.355 0.00% 1,515,609
24-04-19 0.355 +1.43% 1,296,088

Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT

More quotes

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Sector
Biotechnology & Medical Research
Calendar
2024-05-14 - European Society for Medical Oncology Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.42 AUD
Average target price
0.9725 AUD
Spread / Average Target
+131.55%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IMMUTEP LIMITED Stock Immutep Limited
+21.74% 326M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMM Stock